Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: An evaluation by positron emission tomography

American Journal of Cardiology

Volumn 82, Issue 5 A, 1998, Pages 42K-49K

  Mody, Freny Vaghaiwalla ^a   Singh, Bramah N ^a   Mohiuddin, Ishtiaque H ^a   Coyle, Kristine B ^a   Buxton, Denis B ^b,c   Hansen, Herbert W ^b,c   Sumida, Ronald ^b,c   Schelbert, Heinrich R ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Div of Nucl Med and Biophysics   (United States)

^c Division of Nuclear Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROTECTION; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECT; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; GLYCOLYSIS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0032480310     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00536-0     Document Type: Conference Paper

References (35)

1. Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drugs Ther. (Suppl 4):1990;822-823.
2. Kober G., Buck T., Sievert H., Vallbract D. Myocardial protections during percutaneous transluminal coronary angioplasty effects of trimetazidine . Eur Heart J. 13:1992;1109-1115.
3. Kober G., Buck T., Sievert H., Vallbract C. Direct anti-ischemic effect of trimetazidine during coronary angioplasty (PTCA). Circulation. 82:1990;4-1119.
4. Drake-Holland A.J., Belcher P.R., Hynd J., Nobel I.M. Infarct size in rabbits a modified method illustrated by the effects of propranolol and trimetazidine . Basic Res Cardiol. 88:1993;250-258.
5. i regulation in the rat isolated ventricular myocytes. Br J Pharmacol. 117:1996;831-838.
6. Aussedat J., Ray A., Kay L., Verdys M., Harpey C., Rossi A. Improvement of long term preservation of isolated arrested rat heart beneficial effect of antiischemic agent trimetazidine . J Cardiovasc Pharmacol. 21:1993;128-135.
7. Lavachy N., Martin J., Rossi A. Antiischemic effects of trimetazidine 31P NMR spectroscopy in the isolated rat heart . Arch Int Pharmacodyn Ther. 289:1987;97-110.
8. Guanieri C., Muscari C. Beneficial effects of trimetazidine on mitochondrial function and peroxide production in the cardiac muscle. Cardiovasc Drug Ther. 4:1990;814-815.
9. Timour Q., Harpey C., Francoise D., Faucon C. Is the antianginal action of trimetazidine independent of hemodynamic changes. Cardiovasc Drugs Ther. 5:1991;1043-1044.
10. Sellier P., Audoin P., Rayen B., Corona P., Doung T.C., Oubak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol. 33:1987;205-207.
11. Dalla-Volta S., Maraglino G., Della-Valentina P., Viena P., Desideri A. Comparison of trimetazidine with nifedipine in effort angina a double blind, crossover study . Cardiovasc Drugs Ther. 4:1990;853-860.
12. Opie L.H., Thomas M. Propranolol and experimental myocardial infarction substrate effect . Postgrad Med J. 4:(suppl 4):1976;124-132.
13. Kjekshus J.K., Mjos O.D. Effect of free fatty acid on myocardial function and metabolism in ischemic dog heart. J Clin Invest. 52:1972;1767-1776.
14. Mjos O.D., Miller N.E., Riemersma R.A. Effects of p-cholorophenoxyisobutyrate on myocardial free fatty acid elevation during coronary occlusion in dogs. Circulation. 53:1976;494-500.
15. Lopaschuk G.D., Wall S.R., Olley P.M., Davies N.J. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long-chain acylcarnitine. Circ Res. 63:1988;1036-1043.
16. Sodi-Pallares P., Testelli M.R., Fishleder F.L., et al. Effects of intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol. 9:1962;166-181.
17. Maroko P.R., Libby P., Sobel B.E., Bloor C.M., Sybers H.D., Shell W.E., Covell J.W., Braunwald E. Effects of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation. 45:1972;1160-1175.
18. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions Potential for pharmacologic interventions . Cardiovasc Res. 33:1997;243-257.
19. Krivokapich J., Huang S.C., Phelps M.E., Barrio J.R., Watanabe C.R., Selin C.E., Shine K.I. Estimation of rabbit myocardial metabolic rate for glucose using fluorodeoxyglucose. Am J Physiol. 243:1982;H884-H895.
20. Buxton D.B., Schwaiger M., Nguyen A., Phelps M.E., Schelbert H.R. Radiolabelled acetate as a myocardial tricarboxylic acid cycle tracer. Circ Res. 63:1988;623-634.
21. Gambhir S.S., Schwaiger M., Huang S.C., Krivokapich J., Schelbert H.R., Nienaber C.A., Phelps M.E. Simple noninvasive quantification method for measuring myocardial glucose utilization employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med. 30:1989;359-366.
22. Mody Vaghaiwalla F, Singh BN, Mohiuddin I, et al. Delineating a mechanism of action of a novel antianginal agent class. Assessing the hemodynamic, metabolic and substrate extraction effects of trimetazidine using positron emission tomography in a prolonged ischemic dog model. (To be Submitted).
23. i regulation in hypoxic cardiac myocytes from the rat. Fundam Clin Pharmacol. 11:1997;427-439.
24. Williams F.M., Tanda K., Kus M., Williams T.J. Trimetazidine inhibits neutrophil accumulations after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 22:1993;828-833.
25. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Dargie H., Mathias P. Trimetazidine: a new concept in the treatment of angina Comparison with propranolol in patients with stable angina . Br J Clin Pharmacol. 37:1994;279-288.
26. Hugtenberg J.G., Jap J.W., Mathy M.J., Van Heiningen P.N.M., Bohrenn V.A., Heijinis J.B., Boddeke H.W.G., Van Zwieten P.A. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischemia. Arch Int Pharmacodyn Ther. 300:1989;186-208.
27. Pornin M., Harpey C., Allal J., Sellier P., Ourbak P. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease a placebo-controlled study . Clinical Trials and Meta-Analysis. 29:1994;49-56.
28. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 26:1994;949-958.
29. Demaison L., Fantini E., Sentex E., Grynberg A., Athias P. Trimetazidine in vitro influence on heart mitochondrial function . Am J Cardiol. 76:1995;31B-37B.
30. Boucher F.R., Hearse D.J., Opie L.H. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol. 24:1994;45-49.
31. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization theory, procedure, and normal values in the conscious and anesthetized albino rat . J Neurochem. 28:1997;897-916.
32. Ng C.K., Holden J.E., DeGrado T.R., Raffel D.M., Kornguth M.L., Gatley S.J. Sensitivity of myocardial fluorodeoxyglucose lumped constant to glucose and insulin. Am J Physiol. 260:1991;H593-H603.
33. Hariharan R., Bray M., Ganim R., Doenst T., Goodwin G.W., Taegetmeyer H. Fundamental limitations of F18-2-deoxy-2 fluoro-D-glucose for assessing myocardial glucose uptake. Circulation. 91:1995;2435-2444.
34. Ratib O., Phelps M.E., Huang S.C., Selin C.E., Schelbert H.R. Positron tomography with deoxyglucose for estimated local myocardial glucose metabolism. J Nucl Med. 23:1982;577-586.
35. Krivokapich J., Huang S.C., Selin C.E., Phelps M.E. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol. 252:1987;H777-H787.